
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple ...
Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive …